Editas Medicine Receives EMA’s Orphan Medicinal Product … – Nasdaq
Press Telegraph |
Editas Medicine Receives EMA's Orphan Medicinal Product …
Nasdaq CAMBRIDGE, Mass., Sept. 26, 2017– Editas Medicine, Inc., a leading genome editing company, today announced the European Medicines Agency granted. Editas Medicine, Inc. (NASDAQ:EDIT) Moving Today – Down $0.85 |
